Australian patent for PromarkerEndo
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Proteomics International Laboratories Ltd. has secured an Australian patent for its PromarkerEndo diagnostic test for endometriosis, as reported in the filing. This patent acceptance represents a significant milestone for the company, enhancing its intellectual property portfolio and supporting commercialization efforts. The company is also pursuing patent protection in other major jurisdictions to expand its market reach.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Proteomics International Laboratories Ltd. on 6ix
Story so far
Earlier from Proteomics International Laboratories
- Proteomics signs national distribution deal with Healius
- US patent secured for PromarkerEndo
- Proteomics Strategic Plan
- Restructure, Executive Appointment and Board Update
- Appendix 4D and Interim Financial Report
Later from Proteomics International Laboratories
- Appendix 4E and Annual Report
- PromarkerD and PromarkerEso Commercial Rollout Update
- PromarkerEndo Validation and Refinement Complete
- Proteomics International receives $2.0m in R&D tax incentive
- National Rollout of PromarkerD and PromarkerEso
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories